The neonatal Fc receptor: Key to homeostasic control of IgG and IgG‐related biopharmaceuticals
暂无分享,去创建一个
[1] A. Manning,et al. M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study , 2018, Clinical pharmacology and therapeutics.
[2] R. Wells,et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. , 2018, Blood advances.
[3] R. Ober,et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans , 2018, The Journal of clinical investigation.
[4] Zhao-Xue Yu,et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.
[5] Denise M O'Hara,et al. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics , 2017, mAbs.
[6] R. Lledo-Garcia,et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study , 2017, Science Translational Medicine.
[7] Stephen R. Comeau,et al. Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody , 2017, The Journal of Biological Chemistry.
[8] R. Ober,et al. Engineered clearing agents for the selective depletion of antigen-specific antibodies , 2017, Nature Communications.
[9] A. Yamniuk,et al. Fc‐Silent Anti‐CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] T. Igawa,et al. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody , 2017, mAbs.
[11] P. Späth,et al. Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations , 2017, Archivum Immunologiae et Therapiae Experimentalis.
[12] S. Vermeire,et al. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease , 2016, The American Journal of Gastroenterology.
[13] K. Howard,et al. Albumin-based drug delivery: harnessing nature to cure disease , 2016, Molecular and Cellular Therapies.
[14] N. Baroukh,et al. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding , 2016, The Journal of Immunology.
[15] P. Ramsland,et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. , 2015, Molecular immunology.
[16] K. Schwarz,et al. β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system. , 2015, The Journal of allergy and clinical immunology.
[17] W. Lencer,et al. FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin , 2015, The Journal of Immunology.
[18] J. Biedenkapp,et al. Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates , 2015, Front. Immunol..
[19] Inger Sandlie,et al. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics , 2015, Front. Immunol..
[20] Thomas Emrich,et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics , 2014, Proceedings of the National Academy of Sciences.
[21] M. Baranyi,et al. Transgenic Rabbits That Overexpress the Neonatal Fc Receptor (FcRn) Generate Higher Quantities and Improved Qualities of Anti-Thymocyte Globulin (ATG) , 2013, PloS one.
[22] N. Baroukh,et al. Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies , 2013, mAbs.
[23] A. Kaplan. Therapeutic plasma exchange: A technical and operational review , 2013, Journal of clinical apheresis.
[24] B. Carr,et al. Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences , 2011, Drug Metabolism and Disposition.
[25] E. Fiebiger,et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8−CD11b+ dendritic cells , 2011, Proceedings of the National Academy of Sciences.
[26] D. Roopenian,et al. The Neonatal FcR-Mediated Presentation of Immune-Complexed Antigen Is Associated with Endosomal and Phagosomal pH and Antigen Stability in Macrophages and Dendritic Cells , 2011, The Journal of Immunology.
[27] R. Kuijpers,et al. The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha , 2011, British Journal of Ophthalmology.
[28] Tetsu Kobayashi,et al. Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.
[29] J. Marvin,et al. Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.
[30] R. Ober,et al. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice , 2009, Proceedings of the National Academy of Sciences.
[31] J. Andersen,et al. Dependence of antibody-mediated presentation of antigen on FcRn , 2008, Proceedings of the National Academy of Sciences.
[32] C. T. Hehir,et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn , 2008, Proceedings of the National Academy of Sciences.
[33] A. Shaw,et al. Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism1 , 2007, The Journal of Immunology.
[34] A. Bitonti,et al. Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade , 2007, The Journal of Immunology.
[35] G. Vidarsson,et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. , 2006, Blood.
[36] G. Bein,et al. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor α‐chain promoter , 2006 .
[37] D. Roopenian,et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. , 2005, The Journal of clinical investigation.
[38] R. Ober,et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels , 2005, Nature Biotechnology.
[39] P. Hudson,et al. Engineered antibodies , 2003, Nature Medicine.
[40] C. Anderson,et al. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[41] Jin‐Kyoo Kim,et al. Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice , 1996, European journal of immunology.
[42] M. Uhlén,et al. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. , 1996, The Journal of pharmacology and experimental therapeutics.
[43] K. Mostov,et al. An Fc receptor structurally related to MHC class I antigens , 1989, Nature.
[44] J. Kraehenbuhl,et al. Receptor-mediated transport of IgG , 1984, The Journal of cell biology.
[45] F. W. Brambell. The transmission of immunity from mother to young and the catabolism of immunoglobulins. , 1966, Lancet.
[46] F. W. R. BRAMBELL,et al. A Theoretical Model of γ-Globulin Catabolism , 1964, Nature.
[47] R. Porter. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. , 1959, The Biochemical journal.